

Date: November 22, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4210, Telephone Conference.

Contact Person: Dr. Bruce A. Maurer, Scientific Review Administrator, 6701 Rockledge Drive, Room 4210, Bethesda, Maryland 20892, (301) 435-1225.

Name of SEP: Biological and Physiological Sciences.

Date: November 22, 1996.

Time: 8:30 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Michael Micklin, Scientific Review Administrator, 6701 Rockledge Drive, Room 5198, Bethesda, Maryland 20892, (301) 435-1258.

Name of SEP: Clinical Sciences.

Date: November 22, 1996.

Time: 12:00 p.m.

Place: NIH, Rockledge 2, Room 4138, Telephone Conference.

Contact Person: Dr. Anthony Chung, Scientific Review Administrator, 6701 Rockledge Drive, Room 4138, Bethesda, Maryland 20892, (301) 435-1213.

Name of SEP: Microbiological and Immunological Sciences.

Date: November 25, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4210, Telephone Conference.

Contact Person: Dr. Bruce A. Maurer, Scientific Review Administrator, 6701 Rockledge Drive, Room 4210, Bethesda, Maryland 20892, (301) 435-1225.

Name of SEP: Biological and Physiological Sciences.

Date: November 26, 1996.

Time: 11:00 a.m.

Place: NIH, Rockledge 2, Room 4124, Telephone Conference.

Contact Person: Dr. Mushtaq Khan, Scientific Review Administrator, 6701 Rockledge Drive, Room 4124, Bethesda, Maryland 20892, (301) 435-1778.

Name of SEP: Microbiological and Immunological Sciences.

Date: November 26, 1996.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4210, Telephone Conference.

Contact Person: Dr. Bruce A. Maurer, Scientific Review Administrator, 6701 Rockledge Drive, Room 4210, Bethesda, Maryland 20892, (301) 435-1225.

This notice is being published less than 15 days prior to the meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Biological and Physiological Sciences.

Date: December 9, 1996.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 4148, Telephone Conference.

Contact Person: Dr. Philip L. Perkins, Scientific Review Administrator, 6701 Rockledge Drive, Room 4148, Bethesda, Maryland 20892, (301) 435-1718.

Name of SEP: Clinical Sciences.

Date: December 12, 1996.

Time: 8:00 a.m.

Place: Double Tree Hotel, Rockville, MD.

Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435-1783.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 1, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-28799 Filed 11-8-96; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Biological and Physiological Sciences.

Date: November 10-12, 1996.

Time: 8:30 a.m.

Place: Sheraton Airport Hotel, Cleveland, OH.

Contact Person: Dr. Cheryl Corsaro, Scientific Review Administrator, 6701 Rockledge Drive, Room 6172, Bethesda, Maryland 20892, (301) 435-1045.

Name of SEP: Behavioral and Neurosciences.

Date: November 15, 1996.

Time: 9:00 a.m.

Place: Holiday Inn, Bethesda, MD.

Contact Person: Dr. Jane Hu, Scientific Review Administrator, 6701 Rockledge Drive, Room 5168, Bethesda, Maryland 20892, (301) 435-1245.

Name of SEP: Microbiological and Immunological Sciences.

Date: November 20, 1996.

Time: 1:30 p.m.

Place: NIH, Rockledge 2, Room 4182, (Telephone Conference).

Contact Person: Dr. William Branche, Jr., Scientific Review Administrator, 6701 Rockledge Drive, Room 4182, Bethesda, Maryland 20892 (301) 435-1148.

Name of SEP: Microbiological and Immunological Sciences.

Date: November 21, 1996.

Time: 8:00 a.m.

Place: American Inn, Bethesda, MD.

Contact Person: Dr. Sami Mayyasi, Scientific Review Administrator, 6701

Rockledge Drive, Room 4194, Bethesda, Maryland 20892, (301) 435-1216.

Name of SEP: Biological and Physiological Sciences.

Date: November 24-25, 1996.

Time: 6:00 p.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Martin Padarathsingh, Scientific Review Administrator, 6701 Rockledge Drive, Room 4146, Bethesda, Maryland 20892, (301) 435-1717.

Name of SEP: Microbiological and Immunological Sciences.

Date: November 26, 1996.

Time: 2:30 p.m.

Place: NIH, Rockledge 2, Room 4186 (Telephone Conference).

Contact Person: Dr. Gerald Liddel, Scientific Review Administrator, 6701 Rockledge Drive, Room 4186, Bethesda, Maryland 20892 (301) 435-1150.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 5, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-28916 Filed 11-8-96; 8:45 am]

BILLING CODE 4140-01-M

Public Health Service

National Institutes of Health; Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HN (National Institutes of Health) (NIH) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 61 FR 42433, August 15, 1996), is amended to reflect a reorganization within the National Institute of Neurological Disorders and Stroke (NINDS) (HNQ). The reorganization consists of the following: (1) Transfer the functions of the Division of Demyelinating, Atrophic, and Dementing Disorders (DDADD) (HNQ9) relating to neurodegenerative disease to the Division of Stroke and

Trauma (DST) (HNQ6), transfer the remaining functions of the DDADD relating to AIDS, multiple sclerosis and autoimmune disorders to the Division of Convulsive, Developmental and Neuromuscular Disorders (HNQ8), transfer the neural prostheses program activities from the Division of Fundamental Neurosciences (HNQ3) to the DST, retitle DST to the Division of Stroke, Trauma, and Neurodegenerative Disease, and revise its functional statement; (2) abolish the Division of Demyelinating, Atrophic, and Dementing Disorders (HNQ9); (3) transfer the functions of the Developmental Neurology Branch (DNB) of the Division of Convulsive, Developmental, and Neuromuscular Disorders (HNQ83) related to developmental neurobiology, developmental disorders and neurogenetics to the Division of Fundamental Neurosciences (DFN) (HNQ3), transfer the remaining functions of the DNB related to pain and neuromuscular disorders to the Office of the Director of the Division of Convulsive, Developmental, and Neuromuscular Disorders (HNQ8), retitle the DFN to the Division of Fundamental Neuroscience and Developmental Disorders, and revise its functional statement; (4) abolish the Developmental Neurology Branch of the Division of Convulsive, Developmental, and Neuromuscular Disorders (HNQ83); and (5) retitle the Division of Convulsive, Developmental, and Neuromuscular Disorders (HNQ8) to the Division of Convulsive, Infectious, and Immune Disorders and revise its functional statement.

Section HN-B, Organization and Functions, is amended as follows: Under the heading *National Institute of Neurological Disorders and Stroke (HNQ)*, (1) delete the titles and functional statements in their entirety for the Division of Demyelinating, Atrophic, and Dementing Disorders (HNQ9) and Developmental Neurology Branch (HNQ83); (2) delete the titles and functional statements in their entirety for the Division of Fundamental Neurosciences (HNQ3), Division of Stroke and Trauma (HNQ6), and Division of Convulsive, Developmental, and Neuromuscular Disorders (HNQ8) and substitute the following:

Division of Fundamental Neuroscience and Developmental Disorders (HNQ3)

(1) Plans and directs a program of grant and contract support for research and research career development for fundamental cellular, molecular and systems neuroscience, for developmental neurobiology, for

developmental disorders, and for neurogenetics to assure maximum utilization of available resources in the attainment of Institute objectives; (2) maintains surveillance over developments in these program areas and assesses the national need for research, including research on the cause, prevention, diagnosis, and treatment of developmental disorders, and pursues technological development, the application of research findings, and research training and career development in these areas; (3) determines program priorities and recommends funding levels for programs to be supported by grants; (4) determines priorities and funding levels for programs to be supported by contracts; (5) collaborates NIH-wide on national research efforts related to these program areas; (6) prepares reports and analyses of national needs to assist Institute staff and advisory groups in carrying out their responsibilities and in developing new areas of emphasis; and (7) consults with voluntary health organizations and with professional associations in identifying research needs and developing programs to meet these needs.

Division of Stroke, Trauma, and Neurodegenerative Disease (HNQ6)

(1) Plans and directs a program of grant and contract support for research and research career development on stroke, on traumatic injury to the brain and nervous system, including traumatic brain and spinal cord injury, on neurodegenerative disorders, including parkinson's disease and alzheimer's disease, on brain tumors and on the development of artificial prosthetic devices to restore function to the damaged nervous system to assure maximum utilization of available resources in the attainment of Institute objectives; (2) maintains surveillance over developments in these program areas and assesses the national need for research in the cause, prevention, diagnosis, and treatment of convulsive, infectious and immune disorders of the brain and the nervous system, and pursues technological development, the application of research findings, and research training and career development in these areas; (3) determines program priorities and recommends funding levels for programs to be supported by grants; (4) determines priorities and funding levels for programs to be supported by contracts; (5) collaborates NIH-wide on national research efforts related to these program areas; (6) prepares reports and analyses of national needs to assist Institute staff and advisory groups in

carrying out their responsibilities and in developing new areas of emphasis; and (7) consults with voluntary health organizations and with professional associations in identifying research needs and developing programs to meet these needs.

Division of Convulsive, Infectious, and Immune Disorders (HNQ8)

(1) Plans and directs a program of grant and contract support for research and research career development on convulsive disorders, including epilepsy, infectious disorders of the brain and the nervous system, including AIDS, immune disorders of the brain and the nervous system, including multiple sclerosis, disorders related to the sleep mechanisms, and pain to assure maximum utilization of available resources in the attainment of Institute objectives; (2) maintains surveillance over developments in these program areas and assesses the national need for research in the cause, prevention, diagnosis, and treatment of convulsive, infectious and immune disorders of the brain and the nervous system, and pursues technological development, the application of research findings, and research training and career development in these areas; (3) determines program priorities and recommends funding levels for programs to be supported by grants; (4) determines priorities and funding levels for programs to be supported by contracts; (5) collaborates NIH-wide on national research efforts related to these program areas; (6) prepares reports and analyses of national needs to assist Institute staff and advisory groups in carrying out their responsibilities and in developing new areas of emphasis; and (7) consults with voluntary health organizations and with professional associations in identifying research needs and developing programs to meet these needs.

Dated: October 31, 1996.

Harold Varmus,

Director, NIH.

[FR Doc. 96-28803 Filed 11-8-96; 8:45 am]

BILLING CODE 4140-01-M

National Institutes of Health; Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HN (National Institutes of Health) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 61 FR 42433, August 15, 1996), is amended to reflect